Trastuzumab Emtansine: First Global Approval

2013/04/26 by Anita Ballantyne, Anita D. Ballantyne, Sohita Dhillon · 25 citations
Medicine · #HER2/EGFR in Cancer Research #Monoclonal and Polyclonal Antibodies Research #Cancer Treatment and Pharmacology

paper · doi:10.1007/s40265-013-0050-2

Citations

• Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

Cited by

• Glioblastoma cancer stem cells: Biomarker and therapeutic advances. [europepmc]
• Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates. [europepmc]
• Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules. [europepmc]
• An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer. [europepmc]
• Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. [europepmc]
• Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix. [europepmc]
• Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency. [europepmc]
• From Ugi Multicomponent Reaction to Linkers for Bioconjugation. [europepmc]
• How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs. [europepmc]
• Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments. [europepmc]
• In Vitro Cytotoxicity of Trastuzumab (Tz) and Se-Trastuzumab (Se-Tz) against the Her/2 Breast Cancer Cell Lines JIMT-1 and BT-474. [europepmc]
• Rapid and robust cysteine bioconjugation with vinylheteroarenes. [europepmc]
• Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors. [europepmc]
• A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells. [europepmc]
• Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. [europepmc]
• Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. [europepmc]
• Site-specific bioorthogonal protein labelling by tetrazine ligation using endogenous β-amino acid dienophiles. [europepmc]
• Peptides Targeting HER2-Positive Breast Cancer Cells and Applications in Tumor Imaging and Delivery of Chemotherapeutics. [europepmc]
• The History and Development of HER2 Inhibitors. [europepmc]
• A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers. [europepmc]
• Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA Adverse Event Reporting System database. [europepmc]
• Pharmacovigilance study of the association between peripheral neuropathy and antibody-drug conjugates using the FDA adverse event reporting system. [europepmc]
• Targeting FAK improves the tumor uptake of antibody-drug conjugates to strengthen the anti-cancer responses. [europepmc]
• Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database. [europepmc]
• Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs. [europepmc]